title: Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment.
abstract: Development of improved gene transfer methods is needed for gene therapy to achieve its clinical potential. The use of biocompatible polymeric gene carriers has shown effectiveness in overcoming the current problems associated with viral vectors in safety, immunogenicity and mutagenesis. Previous work has demonstrated that repeated, local, non-viral interleukin-12 (IL-12) gene delivery successfully slows down tumor progression, while improving immunogenicity. Combining IL-12 gene delivery with systemic paclitaxel (PCT) chemotherapy as a treatment for various subcutaneous mouse mammary carcinomas, we used PCT with either a biodegradable polymeric solubilizer, HySolv or Cremophor EL for systemic treatment and injected water soluble lipopolymer (WSLP)/plasmid-encoding IL-12 gene (p2CMVmIL-12) complexes local once every week. The amount of lung metastases being essential for survival as well as subcutaneous tumor volume were compared against untreated controls. We showed inhibition of tumor growth and decreased lung metastases in the combined WSLP/p2CMVmIL-12/HySolv group compared to the controls and the PCT only treated groups. Compared to Cremophor, HySolv performed better alone or in combination with IL-12. Using polymeric vectors as gene carrier systems in combination with improved systemic therapies provide evidence for the efficacy and feasibility of polymer-based drug delivery systems. Especially local cytokine gene delivery showed augmentation of systemic chemotherapy while reducing the hosts risk for further systemic toxicity.
authors.affiliation: Center for Controlled Chemical Delivery, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
authors.forename: Margit Maria
authors.initials: MM
authors.lastname: Janát-Amsbury
authors.forename: James W
authors.initials: JW
authors.lastname: Yockman
authors.forename: Minhyung
authors.initials: M
authors.lastname: Lee
authors.forename: Steven
authors.initials: S
authors.lastname: Kern
authors.forename: Darin Y
authors.initials: DY
authors.lastname: Furgeson
authors.forename: Malavosklish
authors.initials: M
authors.lastname: Bikram
authors.forename: Sung Wan
authors.initials: SW
authors.lastname: Kim
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004337:Drug Carriers; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011108:Polymers / Q000008:administration & dosage; D012995:Solubility
chemical_list: D004337:Drug Carriers; D011108:Polymers; D018664:Interleukin-12; D007371:Interferon-gamma; D017239:Paclitaxel